Ligand Pharmaceuticals, Inc. (LGND)
319.55
+7.54
(+2.42%)
USD |
NASDAQ |
Jul 02, 16:00
319.16
-0.39
(-0.12%)
After-Hours: 20:00
Ligand Pharmaceuticals Debt to Equity Ratio : 0.4532 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.4532 |
| December 31, 2025 | 0.4439 |
| September 30, 2025 | 0.4746 |
| June 30, 2025 | 0.0069 |
| March 31, 2025 | 0.0056 |
| December 31, 2024 | 0.0086 |
| September 30, 2024 | 0.0087 |
| June 30, 2024 | 0.0098 |
| March 31, 2024 | 0.0077 |
| December 31, 2023 | 0.0088 |
| September 30, 2023 | 0.0095 |
| June 30, 2023 | 0.0176 |
| March 31, 2023 | 0.1372 |
| December 31, 2022 | 0.1469 |
| September 30, 2022 | 0.1395 |
| June 30, 2022 | 0.1802 |
| March 31, 2022 | 0.2461 |
| December 31, 2021 | 0.395 |
| September 30, 2021 | 0.4071 |
| June 30, 2021 | 0.4099 |
| March 31, 2021 | 0.4907 |
| December 31, 2020 | 0.6433 |
| September 30, 2020 | 0.6591 |
| June 30, 2020 | 0.6627 |
| March 31, 2020 | 0.6876 |
| Date | Value |
|---|---|
| December 31, 2019 | 0.8474 |
| September 30, 2019 | 0.7552 |
| June 30, 2019 | 0.6364 |
| March 31, 2019 | 0.6012 |
| December 31, 2018 | 1.134 |
| September 30, 2018 | 1.166 |
| June 30, 2018 | 1.301 |
| March 31, 2018 | 0.5064 |
| December 31, 2017 | 0.656 |
| September 30, 2017 | 0.6031 |
| June 30, 2017 | 0.6308 |
| March 31, 2017 | 0.6527 |
| December 31, 2016 | 0.7105 |
| September 30, 2016 | 0.7162 |
| June 30, 2016 | 0.734 |
| March 31, 2016 | 0.5613 |
| December 31, 2015 | 1.018 |
| September 30, 2015 | 0.6946 |
| June 30, 2015 | 2.904 |
| March 31, 2015 | 5.650 |
| December 31, 2014 | 7.457 |
| September 30, 2014 | 4.371 |
| June 30, 2014 | 0.042 |
| March 31, 2014 | 0.0888 |
| December 31, 2013 | 0.1836 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Organon & Co. | 9.490 |
| Johnson & Johnson | 0.6773 |
| Eli Lilly & Co. | 1.390 |
| Merck & Co., Inc. | 1.071 |
| ANI Pharmaceuticals, Inc. | 1.092 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.532B |
| Total Liabilities (Quarterly) | 534.78M |
| Shareholders Equity (Quarterly) | 997.32M |
| Current Ratio | 21.28 |
| Net Debt Paydown Yield | -2.22% |